The London stock market has faced recent challenges, with the FTSE 100 and FTSE 250 indices experiencing declines due to weak trade data from China impacting global sentiment. Despite these broader market fluctuations, there are still opportunities for investors interested in smaller or newer companies through penny stocks. While the term “penny stocks” might seem outdated, they can still represent valuable investment opportunities when backed by strong financial health and growth potential.
|
Name |
Share Price |
Market Cap |
Financial Health Rating |
|
Polar Capital Holdings (AIM:POLR) |
£4.965 |
£478.61M |
★★★★★★ |
|
Begbies Traynor Group (AIM:BEG) |
£0.972 |
£153.33M |
★★★★★★ |
|
Foresight Group Holdings (LSE:FSG) |
£3.70 |
£422.49M |
★★★★★★ |
|
ME Group International (LSE:MEGP) |
£1.976 |
£744.58M |
★★★★★★ |
|
Stelrad Group (LSE:SRAD) |
£1.405 |
£178.93M |
★★★★★☆ |
|
Secure Trust Bank (LSE:STB) |
£3.58 |
£68.28M |
★★★★☆☆ |
|
Luceco (LSE:LUCE) |
£1.17 |
£180.45M |
★★★★★☆ |
|
Next 15 Group (AIM:NFG) |
£3.48 |
£346.11M |
★★★★☆☆ |
|
Tristel (AIM:TSTL) |
£3.975 |
£189.58M |
★★★★★★ |
|
Helios Underwriting (AIM:HUW) |
£1.99 |
£141.97M |
★★★★★☆ |
Click here to see the full list of 445 stocks from our UK Penny Stocks screener.
We’re going to check out a few of the best picks from our screener tool.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Futura Medical plc researches, develops, and sells pharmaceutical and healthcare products for sexual health, with a market cap of £95.67 million.
Operations: The company generates £8.40 million from the development and commercialisation of MED3000.
Market Cap: £95.67M
Futura Medical, with a market cap of £95.67 million, is currently unprofitable but has shown promise through its recent successful WSD4000 study for sexual dysfunction treatment in women. The company is debt-free and has no long-term liabilities, which can be advantageous for managing financial stability. Despite being unprofitable, it has reduced losses by 6.8% annually over the past five years and is trading significantly below its estimated fair value. Analysts forecast substantial growth in earnings at 188.27% per year, suggesting potential upside if the company successfully commercializes its products and manages cash constraints effectively.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Kodal Minerals PLC, with a market cap of £88.08 million, is involved in the exploration and evaluation of mineral resources in the United Kingdom and West Africa through its subsidiaries.